{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:46:36Z","timestamp":1772505996846,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81720108002"],"award-info":[{"award-number":["81720108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002949","name":"Government of Jiangsu Province","doi-asserted-by":"publisher","award":["2015-WSN-050"],"award-info":[{"award-number":["2015-WSN-050"]}],"id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09734007"],"award-info":[{"award-number":["2018ZX09734007"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020779","name":"Jiangsu Provincial Special Program of Clinical Medical Science","doi-asserted-by":"publisher","award":["BE2017751"],"award-info":[{"award-number":["BE2017751"]}],"id":[{"id":"10.13039\/501100020779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.neo.2020.10.004","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T09:32:16Z","timestamp":1603445536000},"page":"714-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["SHC014748M, a novel selective inhi-bitor of PI3K\u03b4, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"22","author":[{"given":"Lei","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2020.10.004_bib0001","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2020.10.004_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-13150-4_1","article-title":"Epidemiology and etiology of non-Hodgkin lymphoma","volume":"165","author":"Chiu","year":"2015","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.neo.2020.10.004_bib0003","series-title":"SEER Stat Fact Sheets: Non-Hodgkin lymphoma","year":"2012"},{"key":"10.1016\/j.neo.2020.10.004_bib0004","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.neo.2020.10.004_bib0005","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.neo.2020.10.004_bib0006","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.neo.2020.10.004_bib0007","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2020.10.004_bib0008","doi-asserted-by":"crossref","first-page":"k3204","DOI":"10.1136\/bmj.k3204","article-title":"Non-Hodgkin lymphoma","volume":"362","author":"Bowzyk","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.neo.2020.10.004_bib0009","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2012.09.004","article-title":"Management of indolent lymphoma: where are we now and where are we going","volume":"26","author":"Lunning","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.neo.2020.10.004_bib0010","series-title":"WHO Classification of Tumours of Haematopoietic and Lympoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.neo.2020.10.004_bib0011","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study","volume":"36","author":"Cheson","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2020.10.004_bib0012","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ajh.25228","article-title":"Duvelisib, an oral dual PI3K-\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study","volume":"93","author":"Flinn","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.neo.2020.10.004_bib0013","unstructured":"National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology (NCCN Guidelines): B-cell lymphomas (version 1.2017), 2016. Available online: https:\/\/www.nccn.org."},{"key":"10.1016\/j.neo.2020.10.004_bib0014","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","article-title":"Targeting the B cell receptor pathway in non-Hodgkin lymphoma","volume":"27","author":"Valla","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.neo.2020.10.004_bib0015","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.neo.2020.10.004_bib0016","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2020.10.004_bib0017","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cellsig.2010.10.002","article-title":"Phosphoinositide 3-kinase \u03b4 (PI3K\u03b4) in leukocyte signaling and function","volume":"23","author":"Fung-Leung","year":"2011","journal-title":"Cell Signal"},{"key":"10.1016\/j.neo.2020.10.004_bib0018","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","article-title":"PI3K isoforms in cell signalling and vesicle trafficking","volume":"20","author":"Bilanges","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neo.2020.10.004_bib0019","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neo.2020.10.004_bib0020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.neo.2020.10.004_bib0021","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase \u03b4 inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.neo.2020.10.004_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neo.2020.10.004_bib0023","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neo.2020.10.004_bib0024","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neo.2020.10.004_bib0025","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","article-title":"PI3K isoforms in cell signalling and vesicle trafficking","volume":"20","author":"Bilanges","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neo.2020.10.004_bib0026","unstructured":"Center for Drug Evaluation and Research: Application Number: 205858Orig1s000. Available online: https:\/\/www.fda.gov\/drugs."},{"key":"10.1016\/j.neo.2020.10.004_bib0027","unstructured":"ZYDELIG (idelalisib tablets) Gilead Sciences, Inc.; Foster City, CA: 2014. Full prescribing information. Available online: https:\/\/www.fda.gov\/media\/100575\/download."},{"key":"10.1016\/j.neo.2020.10.004_bib0028","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2352-3026(17)30028-5","article-title":"Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the alliance for clinical trials in oncology A051201 and A051202 phase 1 trials","volume":"4","author":"Smith","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.neo.2020.10.004_bib0029","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.neo.2020.10.004_bib0030","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4, \u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.neo.2020.10.004_bib0031","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/1060028019833992","article-title":"Copanlisib. An intravenous phosphatidylinositol 3-kinase (PI3K) inhibitor for the treatment of relapsed follicular lymphoma","volume":"53","author":"Eltantawy","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.neo.2020.10.004_bib0032","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14728214.2018.1479396","article-title":"Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma","volume":"23","author":"Rodgers","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.neo.2020.10.004_bib0033","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.neo.2020.10.004_bib0034","unstructured":"Methods of Treating Hematological Disorders with Quinazolinone Compounds in Selected Subjects. 2011."},{"key":"10.1016\/j.neo.2020.10.004_bib0035","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.neo.2020.10.004_bib0036","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2007-05-089409","article-title":"Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia","volume":"110","author":"Burkle","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.neo.2020.10.004_bib0037","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neo.2020.10.004_bib0038","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.neo.2020.10.004_bib0039","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2147\/OTT.S102573","article-title":"Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential","volume":"9","author":"Barrientos","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.neo.2020.10.004_bib0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ceb.2017.02.007","article-title":"PI3K signaling in cancer: beyond AKT","volume":"45","author":"Lien","year":"2017","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.neo.2020.10.004_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.0034","article-title":"Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer: a review","author":"Esposito","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.neo.2020.10.004_bib0042","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.neo.2020.10.004_bib0043","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1038\/onc.2013.265","article-title":"PI3K in cancer-stroma interactions: bad in seed and ugly in soil","volume":"33","author":"Hirsch","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2020.10.004_bib0044","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cell.2013.04.031","article-title":"RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms","volume":"153","author":"Fritsch","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neo.2020.10.004_bib0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","article-title":"Oncogenic PI3K and its role in cancer","volume":"18","author":"Samuels","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.neo.2020.10.004_bib0046","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri2036","article-title":"PI3K\u03b4 and PI3K\u03b3: partners in crime in inflammation in rheumatoid arthritis and beyond","volume":"7","author":"Rommel","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neo.2020.10.004_bib0047","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/onc.2008.246","article-title":"Drug discovery approaches targeting the PI3K\/Akt pathway in cancer","volume":"27","author":"Garcia-Echeverria","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2020.10.004_bib0048","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1074\/jbc.274.16.10963","article-title":"Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase","volume":"274","author":"Bi","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neo.2020.10.004_bib0049","first-page":"169","article-title":"Early embryonic lethality in mice deficient in the p110\u03b2 catalytic subunit of PI 3-kinase","volume":"13","author":"Bi","year":"2002","journal-title":"Mamm Genome"},{"key":"10.1016\/j.neo.2020.10.004_bib0050","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.287.5455.1040","article-title":"Function of PI3K\u03b3 in thymocyte development, T cell activation, and neutrophil migration","volume":"287","author":"Sasaki","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neo.2020.10.004_bib0051","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-065X.2008.00750.x","article-title":"Fine tuning the immune response with PI3K","volume":"228","author":"Fruman","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.neo.2020.10.004_bib0052","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/labinvest.3780061","article-title":"Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models","volume":"80","author":"Bryant","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.neo.2020.10.004_bib0053","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.clml.2016.08.011","article-title":"Indolent lymphomas that present with clinically aggressive features: a subset of low-grade lymphomas with a behavior inconsistent with the histologic diagnosis","volume":"16","author":"Cabanillas","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.neo.2020.10.004_bib0054","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.neo.2020.10.004_bib0055","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558620301597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558620301597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:07:58Z","timestamp":1761484078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558620301597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1476558620301597"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2020.10.004","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SHC014748M, a novel selective inhi-bitor of PI3K\u03b4, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2020.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}